Safety assessment of sodium zirconium cyclosilicate: A FAERS-based disproportionality analysis.
Sodium zirconium cyclosilicate (SZC) is a novel therapeutic agent for hyperkalemia. However, limited reports have described its real-world safety. In this study, we used the Food and Drug Administration Adverse Event Reporting System (FAERS) database to evaluate the safety profilet of SZC. This retr...
Saved in:
| Main Authors: | Yongfei Yu, Kaiyu Zhang, Jinglin Gao, Guoshun Huang, Chen Yong, Yuan Wei, Enchao Zhou |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0320585 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Intermittent sodium zirconium cyclosilicate for the prevention of hyperkalemia in chronic kidney disease
by: Jack Kit-Chung Ng, et al.
Published: (2025-05-01) -
Sodium Zirconium Cyclosilicate in the Gastrointestinal Tract Mimicking an Acute Gastrointestinal Bleed on CT
by: John J. Hines, et al.
Published: (2025-04-01) -
WCN25-677 EFFICACY AND SAFETY OF SODIUM ZIRCONIUM CYCLOSILICATE IN MANAGEMENT OF HYPERKALEMIA IN CHRONIC KIDNEY DISEASE
by: Anass Qasem, et al.
Published: (2025-02-01) -
Duration of sodium zirconium cyclosilicate treatment and continuation of RAASi therapy after a hyperkalaemia episode
by: Charles V. Pollack Jr., et al.
Published: (2025-06-01) -
Sodium zirconium cyclosilicate versus sodium polystyrene sulfonate for treatment of hyperkalemia in hemodialysis patients: a randomized clinical trial
by: Mohamed Mamdouh Elsayed, et al.
Published: (2025-05-01)